Stifel analyst, Stephen Willey, reiterated his Buy rating on shares of Dicerna Pharmaceuticals (NASDAQ: DRNA) after the company announced a ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE